Summary.-Measurement of in vitro and in vivo resistance to daunorubicin in AML patients suggests that there is no simple correlation between the two.
In a patient who became clinically resistant and whose cells showed a parallel increased resistance in vitro we found the acquisition of multiple drug resistance. The increased in vitro resistance to daunorubicin could to some extent be overcome by conjugating daunorubicin to DNA. DAUNORUBICIN is commonly combined with other agents to induce remission in patients presenting with acute myelogenous leukaemia (AML). For some time the Medical Oncology Unit at St Bartholomew's Hospital used a combination of cytosine arabinoside and daunorubicin to induce remission (Crowther et al., 1973) . Complete remission is achieved in a significant proportion of patients. However, despite maintenance chemotherapy, relapse almost inevitably occurs and attempts to induce a second remission are necessary. The incidence of a second complete remission in this group is considerably less than in untreated patients (Beard and Fairley, 1974) , but the biochemical mechanism of this resistance is not known. We wondered whether the peripheral cells of those AML patients who are clinically resistant to daunorubicin might be more resistant to daunorubicin in vitro. Using the technique of culturing peripheral myeloblasts from AML patients (Balkwill, Pindar and Crowther, 1974) the ability of the cells to incorporate 3H-thymidine was measured. 3H-thymidine was added to the culture to give a final concentration of 0 5 ,uCi/ml and incubation continued for a further 16 h. Cells were then harvested and 3H-thymidine uptake was measured according to Balkwill et al. (1974) . The results of Balkwill et al. (1974) show that AML cells cultured under these conditions are replicating during the time we do our assay. This strongly suggests that the reduction we measure in 3H-thymidine incorporation reflects cell-killing, although we have not directly measured this. A typical incorporation curve is shown in the Figure. The drug concentration at which the incorporated counts were reduced by half (the TI50) was taken as a guide to the in vitro drug sensitivity. The same approximate value was repeatedly obtained for all cells from the same patient, whether or not fresh or frozen cells were used. Tables I and II show the results obtained for our series of patients. Table I gives the results with pre-treatment cells; Table II (90) 225 (95) 30 (60) 154 (96) 69 (91) 60 (95) 28 (39) 6-3 (41) 33 (59) 96 (74) 11 ( The TI50 is calculated with respect to the daunorubicin added to the cell cultures whether or not it was conjugated to DNA. This experiment has been repeated with essentially the same result. a simultaneous acquisition of multiple drug resistance by P.J.'s cells. This is particularly interesting since P.J. had never been exposed clinically to adriamycin or puromycin although she had received cytosine arabinoside. It could be that this is due to a membrane change which might be by-passed by fixing the daunorubicin to a large polymer such as DNA (Sokal et al., 1973) . We therefore compared the in vitro sensitivity of P.J.'s cells and the cells of several other AML patients to daunorubicin conjugated to DNA and unconjugated daunorubicin. 
DISCUSSION
Our results suggest that the measurement of in vitro drug resistance in this system is not a reliable indication of the clinical response a patient will show to drug therapy. In this study, however, the number of patients tested is small.
In the single instance where drug resistance in vitro parallels the clinical picture we are struck by the simultaneous acquisition of resistance to several drugs. A similar cross-resistance phenomenon has previously been reported in tissue culture cells exposed to increasing amounts of drug in vitro (Minor, 1974) . A possible explanation for this cross-resistance is that a membrane change has occurred affecting the transport of these drugs into the cells, and indeed membrane changes affecting daunorubicin transport have been reported. Ehrlich ascites cells exposed in vitro to daunorubicin undergo selection to produce a cell-line 5 times more resistant to daunorubicin than the parent cell-line (Dan0, Frederiksen and Hellung-Larsen, 1972 ). This resistant cell has been shown to be resistant because of a permeability change and it appears that the drug-resistance in this instance is due to active expulsion of daunorubicin from the cells (Dan0 1973 ). Attempts to demonstrate this effect in P.J.'s cells with 3H-puromycin have failed, however, owing to the fragility of the cells after culture.
Our evidence that P.J.'s cells are more susceptible in vitro to daunorubicin-DNA than to unconjugated daunorubicin is consistent with the acquisition of an altered permeability. This finding may indicate that in cases of clinical resistance paralleled by in vitro resistance the therapy might, with advantage, include drugs conjugated to DNA or some other large carrier molecule.
We have no experimental evidence concerning the mechanisms by which such variants arise. Unfortunately, although the life of AML cells cultured under these conditions can be as long as 2-3 months (Balkwill and Oliver, 1976 ) the ability of P.J.'s cells to be trypsinized and continue to replicate has proved inadequate to allow us to select and investigate revertants.
